Accretion Pharmaceuticals Ltd
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit |
Ratios
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Capacity Utilization - Capsules % ・Standalone data |
|
|||
| Capacity Utilization - External Preparations % ・Standalone data |
||||
| Capacity Utilization - Oral Liquid % ・Standalone data |
||||
| Capacity Utilization - Oral Powder % ・Standalone data |
||||
| Capacity Utilization - Tablets % ・Standalone data |
||||
| Direct Export Revenue Share % ・Standalone data |
||||
| Sales on Contract Manufacturing / Loan License Revenue Share % ・Standalone data |
||||
| Top 10 Customer Revenue Concentration % ・Standalone data |
||||
Extracted by Screener AI
Documents
Announcements
-
Shareholders meeting
- Revised postal ballot results: five special resolutions passed, including borrowing limit increase and charge creation.
-
Amendment to AOA/MOA
- Postal ballot approved 1 Sep 2026 object clause change; MOA amended on 9 Oct 2026.
-
Shareholders meeting
- Postal ballot passed five special resolutions, including MOA alteration, higher borrowing limits, and mortgage/charge creation.
-
Shareholders meeting
- Postal ballot passed 5 special resolutions on MOA alteration, borrowing limits, charges, and subsidiary support.
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
- Accretion Pharmaceuticals says Regulation 27(2) corporate governance report not applicable for quarter ended 30 September 2026.
Annual reports
-
Annual Report 2026
from nse
-
Annual Report 2025
from nse
-
Annual Report 2025
from web
Concalls
-
May 2026PPT
-
Nov 2025Transcript PPT REC
Business Profile[1]
The company manufactures pharmaceutical formulations, including both generic and branded products. It offers contract and third-party manufacturing services for domestic and international markets. Its clientele includes private institutions, government sectors (state and central), and reputed pharmaceutical companies.